Endologix Inc. (NASDAQ:ELGX) shares saw unusually-strong trading volume on Friday . Approximately 1,384,534 shares changed hands during trading, an increase of 44% from the previous session’s volume of 958,685 shares.The stock last traded at $14.14 and had previously closed at $14.27.

A number of equities analysts recently weighed in on ELGX shares. JPMorgan Chase & Co. started coverage on shares of Endologix in a report on Monday, April 4th. They set an “overweight” rating and a $11.00 target price on the stock. Zacks Investment Research upgraded shares of Endologix from a “sell” rating to a “hold” rating in a report on Monday, April 4th. Royal Bank Of Canada upped their price objective on shares of Endologix from $11.00 to $15.00 and gave the company an “outperform” rating in a report on Tuesday, May 10th. BMO Capital Markets reiterated a “hold” rating and issued a $11.50 price objective on shares of Endologix in a report on Tuesday, May 10th. Finally, Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Endologix in a report on Tuesday, May 10th. One equities research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $14.55.

The firm’s market cap is $1.15 billion. The company’s 50-day moving average is $13.21 and its 200-day moving average is $10.48.

Endologix (NASDAQ:ELGX) last issued its quarterly earnings data on Monday, May 9th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.01. During the same quarter in the previous year, the business posted ($0.14) EPS. The business earned $42.40 million during the quarter, compared to analyst estimates of $38.78 million. The company’s quarterly revenue was up 15.5% on a year-over-year basis. Analysts anticipate that Endologix Inc. will post ($0.79) EPS for the current fiscal year.

In other Endologix news, Director Gregory D. Waller sold 7,800 shares of the firm’s stock in a transaction on Friday, June 3rd. The stock was sold at an average price of $12.86, for a total transaction of $100,308.00. Following the transaction, the director now directly owns 27,728 shares in the company, valued at approximately $356,582.08. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John D. Mcdermott sold 6,116 shares of the firm’s stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $12.55, for a total value of $76,755.80. Following the transaction, the chief executive officer now owns 663,624 shares in the company, valued at $8,328,481.20. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Endologix stock. California State Teachers Retirement System increased its stake in shares of Endologix Inc. (NASDAQ:ELGX) by 1.8% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 124,973 shares of the company’s stock after buying an additional 2,243 shares during the period. California State Teachers Retirement System owned 0.18% of Endologix worth $1,237,000 as of its most recent filing with the SEC.

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.